Here’s a look at today’s headlines:
Freeport-McMoRan Inc. announced today the completion of its at-the-market offering of common stock announced on August 10, 2015. FCX raised $1 billion in gross proceeds through the sale of 96.7 million shares of FCX common stock in open market transactions since August 10, 2015. The shares were issued pursuant to Freeport McMoRan’s shelf registration statement.
The Office of Alumni Affairs has announced the names of three individuals that will receive alumni awards for their leadership and contributions to the community. New Mexico State Senator Howie Morales is receiving the Distinguished Alumnus Ambassador Award. Dr. Lorraine Morales is receiving the Distinguished Alumna Ambassador award. Alfred Ogas is receiving the Outstanding Alumnus Ambassador award.
Kevin Lenkner, the new Executive Director for the Mimbres Region Arts Council, acknowledged the “great foundation” that the previous director, Faye McCalmont, and the board have built. “The board has asked me to build on that foundation and add to it.” Lenkner said “there are things that are working well for MRAC and there are things that I think need to be explored. I want more ideas on education and the future of the arts in the community. I need more ideas on art and creativity. We can offer things that complement and supplement what is available in the schools. The student outreach at Pickamania was great for me to see.” He said his short-term goals include listening to as many people as possible, such as artists, performers, social studies folks and educators.
The Town of Silver City Council will hold a public hearing during its regular Council Meeting scheduled for Tuesday, September 22nd at 6 pm in the Grant County Administration Center. The Hearing will include approval or disapproval of a restraint Liquor License with Patio Service to Ditrwater Enterprises, LCC, Vicki’s Eatery, and a waiver of NMSA 1978 Section 60 for alcohol sales near a church or school.
Multiple drugs to combat bioterrorism threats and other life-threatening bacterial infections will be developed under a public-private partnership agreement between the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) and AstraZeneca, a global biopharmaceutical company.
